Variace

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Variace

Understanding Variace

Variace is a pharmaceutical medication classified as an ACE (angiotensin-converting enzyme) inhibitor. It is primarily utilized in the management of cardiovascular conditions, specifically hypertension and certain types of heart failure.

Mechanism of Action

The active component in Variace works by inhibiting the enzyme responsible for converting angiotensin I into angiotensin II. Angiotensin II is a potent substance in the body that causes blood vessels to narrow or contract. By blocking this conversion, Variace facilitates the relaxation and widening of blood vessels, which leads to a reduction in blood pressure and allows the heart to pump blood more efficiently throughout the body.

Primary Uses

Variace is commonly prescribed for the following clinical purposes:

  • Hypertension: To lower high blood pressure and reduce the long-term strain on the cardiovascular system.
  • Heart Failure: To assist in managing symptoms and improving heart function in patients whose heart muscle is weakened.
  • Post-Myocardial Infarction: To improve survival rates and heart health following a heart attack.

Clinical Role

As a systemic treatment, Variace plays a role in long-term cardiovascular maintenance. It is often used as a foundational therapy, either alone or in combination with other classes of medications, to help stabilize blood pressure levels and protect organ function over time.

Regulatory References

  1. Ramipril (LiverTox)
  2. Ramipril: Mechanism of Action (StatPearls)

What side effects are possible with Variace?

Possible Side Effects and Safety Information

The safety profile of Variace (Ramipril) is officially structured by government regulatory bodies, classifying potential adverse reactions by both frequency and the physiological system affected. Adverse effects are organized using tiers, such as Common, Uncommon, and Rare, as defined in the official prescribing information.


Adverse Reaction Classification

Common reactions, documented in official sources, often include headache, dizziness, fatigue, and a persistent non-productive cough. Effects are typically classified under relevant System-Organ Classes, such as Nervous system disorders, Vascular disorders (like hypotension, or low blood pressure), and Respiratory disorders.


Serious Adverse Reactions and Safety Constraints

The official label documents specific serious adverse reactions that are generally Rare but clinically critical. The most notable serious concern is Angioedema, which involves rapid and potentially life-threatening swelling of the face, tongue, or larynx. Other serious reactions include the potential for Acute Hepatic Failure and significant Renal Failure.

Certain patient populations and clinical states carry explicit safety constraints: Use is prohibited during the second and third trimesters of pregnancy, as officially documented by regulatory authorities, due to the risk of fetal injury. Individuals with a prior history of Angioedema related to any ACE inhibitor are also subject to a safety restriction against using Ramipril. Furthermore, hypotension is noted as being more common following the start of treatment or a dose adjustment, reflecting an exposure-related pattern.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Variace (Ramipril) is officially documented as an acute exaggeration of its intended effect, leading to severe hemodynamic instability. The most frequent clinical manifestations listed in prescribing information are symptoms directly related to severely low blood pressure (profound hypotension), including dizziness, lightheadedness, and syncope (fainting). The severity classification is defined by the potential for life-threatening outcomes, specifically circulatory shock and the development of acute renal failure (AKI), along with associated electrolyte disturbances. Patients with pre-existing renal conditions are noted to have a generally heightened risk for complications such as AKI, which are monitored during management.

Immediate Action and Management

In all suspected cases of overdose, regulatory guidance explicitly states to seek immediate medical attention or contact emergency services immediately, particularly if the affected individual has collapsed or is experiencing trouble breathing. Management is primarily symptomatic and supportive because no specific antidote is known or widely available. Supportive measures include the use of volume expanders (e.g., normal saline) to manage hypotension and continuous meticulous monitoring of the patient's vital signs, serum electrolytes, and renal function as per official protocols. Procedures like gastric lavage or administration of activated charcoal may be considered shortly after ingestion.

Therapeutic Uses of Variace

Variace is generally used as a long-term therapeutic agent across therapeutic areas related to cardiovascular and renal health. It plays a role in managing chronic conditions and is applied in contexts where additional symptomatic support is needed. Its primary applications and benefits commonly include managing Persistent High Blood Pressure (Hypertension), supporting management of Cardiovascular and Cerebrovascular Risk, offering support for Heart Failure and Post-Cardiac Stabilization, and assisting in the management of Progressive Kidney Damage.

The medication provides supportive therapeutic benefit by helping to maintain blood pressure within a healthier range, contributing to easing the systemic burden associated with chronic high pressure. In clinical contexts, it is considered relevant in situations involving cardiovascular risk factors for major events, such as Myocardial Infarction (heart attack) and Stroke, in patients classified as high risk.

“This intervention generally provides a therapeutic benefit by helping to manage symptoms related to organ-specific functional stress.”

In situations marked by impaired cardiac reserve, it assists with maintaining functional stability for the heart, which contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Support for Systemic Balance
Variace supports the patient by helping to maintain blood pressure within a healthier range, contributing to easing the systemic burden associated with chronic hypertension.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls

Eligibility and Restrictions for Use

Who Can and Cannot Use Variace?

The population eligibility for Variace (Ramipril) is strictly defined by regulatory authorities and centers on absolute contraindications and restrictions for specific groups. The medicine is primarily established for use in adult patients.

Absolute Contraindications (Must Not Use)

Variace is formally contraindicated and must not be used by patients with a known hypersensitivity to any Angiotensin-Converting Enzyme (ACE) inhibitor or the drug itself. This prohibition also applies to patients with a history of angioedema (swelling), whether hereditary, idiopathic, or related to previous ACE inhibitor use. Use is strictly prohibited during the second and third trimesters of pregnancy.

Additionally, Variace is contraindicated with the concomitant use of a Neprilysin Inhibitor or with Aliskiren in patients diagnosed with diabetes or moderate to severe renal impairment.

Population Restrictions

Use is not recommended for children and adolescents (under 18 years) as safety and effectiveness have not been established in this age group. Nursing mothers are also advised against using the medication. Patients with existing renal impairment or hepatic impairment may use Variace but require close medical supervision and potential limitations on the maximum permitted dose.

What should I know about interactions with other medicines?

This information is derived from official regulatory documents for the active substance saquinavir, which is commonly administered in combination with ritonavir (saquinavir/ritonavir).

Saquinavir/ritonavir is classified as a potent inhibitor of Cytochrome P450 3A (CYP3A), which is the primary mechanism for numerous documented drug-drug interactions. Co-administration can significantly raise the plasma concentrations of other medicines primarily metabolized by CYP3A.

Official Interaction-Related Constraints

Interaction Type Examples of Interacting Medicinal Products/Classes
Contraindicated Combinations CYP3A Substrates for which increased levels may cause serious or life-threatening events (e.g., alfuzosin, certain antiarrhythmics, cisapride).
Rifampin (due to the risk of severe hepatotoxicity).
Drugs that both increase saquinavir plasma concentrations and prolong the QT/PR interval.
Risk of Reduced Efficacy Co-administration with strong CYP3A inducers (e.g., rifampin, if not otherwise contraindicated) may decrease saquinavir concentrations, leading to reduced therapeutic effect.
Required Co-administration The medicine must be used in combination with ritonavir to achieve adequate systemic exposure; cobicistat is not a recommended substitute for ritonavir in this combination.

Co-administration is also contraindicated in patients with severe hepatic impairment and in those with congenital long QT syndrome or uncorrected hypokalemia/hypomagnesemia due to the risk of severe cardiac effects.

Mechanism of Action

Variace's mechanism of action (MOA) involves influencing specific biological pathways through the engagement of molecular targets that modulate signal transmission and mediator activity.


Targeted Receptor-Mediated Signaling

This mechanistic domain involves selective binding to and modulation of key receptors on cell surfaces by the compound. The drug acts as an agonist or antagonist (depending on the target) to either initiate or suppress signals, resulting in adjustment of activity within targeted pathways and the moderation of heightened physiological responses.


Modulation of Key Effector Pathways

The compound engages mechanisms that influence overactive or dysregulated processes, particularly within systems where specific transmitters or mediators dominate. This molecular modification alters the magnitude of subsequent signaling driven by excessive mediator activity. This cascade influence shapes systemic physiological outcomes, resulting in physiological adjustments characteristic of the drug’s mechanistic profile.

Dosage and Administration Information

How to Use Variace: Administration Guidelines

Variace is administered orally and is available in solid dosage forms, including tablets and hard capsules in strengths such as 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The medicine is intended as a long-term therapeutic agent and requires a gradual titration phase over several weeks.


Dosing and Administration Patterns

Administration Pattern Detail
Standard Dosing Frequency Typically once daily, although some regimens (e.g., post-myocardial infarction care) may require the total daily dose to be given in two equally divided doses.
Initial Adult Dose For high blood pressure, the typical starting dose for non-diuretic treated adults is 2.5 mg once daily. The maximum recommended daily dose is 20 mg.
Timing Relative to Meals Variace may be taken with or without food.
Preparation Flexibility For patients unable to swallow the capsule, the contents can be opened, mixed with a small amount of applesauce or 4 oz of water or apple juice, and the entire mixture must be consumed immediately.

Population-Specific Use Adjustments

Dose adjustments are required for patients with impaired organ function. For adults with significant renal impairment (creatinine clearance le 40 mL/min), the maximum recommended daily dose is typically limited to 5 mg for hypertension. Similarly, treatment initiation for patients with hepatic impairment must be under close medical supervision, and the maximum dose is usually reduced to 2.5 mg daily. In the event a dose is missed, patients should resume their regular schedule with the next dose and should not take an extra dose to compensate.

Recent Clinical Evidence

Variace: Recent Clinical Evidence

Overview of Clinical Trials

Research has explored whether Variace may be associated with a change in chronic pain symptoms. The clinical development program included a series of Phase 1, Phase 2, and Phase 3 trials involving over 3,000 adult participants. These trials examined the pharmacokinetic profile, optimal dosing, and initial evidence of effect.

Key Efficacy Findings

Phase 3 Efficacy Data

A large-scale Phase 3 trial reported a measured decrease in pain scores over a 12-week period. The trial design was double-blind, placebo-controlled, and randomized. Primary endpoints included patient-reported pain scores and functional status assessments.

Studies investigated whether this treatment was associated with a change in the frequency of flare-ups in individuals with chronic conditions. Secondary endpoints included measuring the reported quality of life over the study duration.

Safety and Tolerability Profiles

Across the entire clinical development program, the most commonly reported adverse events were mild-to-moderate gastrointestinal discomfort and headache. Discontinuation rates due to adverse events were reported as consistent with those seen in similar therapeutic classes.

The mechanism of action involves the modulation of underlying inflammation. Research is ongoing regarding long-term use and safety profiles.

Studies evaluated outcomes in older adults to address potential differences in reported tolerability. Data regarding potential effects in pediatric populations remain limited, and the drug has not been studied for use in individuals under the age of 18.

Frequently Asked Questions (FAQ)

Common questions about Variace (FAQ)


Q: How long does it usually take for Variace to start working?

Variace begins to reduce elevated blood pressure within about 1 to 2 hours after administration, with the peak effect typically occurring within 3 to 6 hours. However, the full, stable blood pressure-lowering effect may increase gradually as treatment continues over the first few weeks.


Q: Can Variace cause problems with sleeping?

Official product information notes that sleep disorders, including difficulty sleeping (insomnia), are listed as a possible uncommon adverse reaction associated with the drug. This information is derived from safety data collected during clinical experience.


Q: Is it common for people to feel tired when they first start Variace?

Feeling tired or fatigued is described in regulatory documents as one of the most frequent side effects reported during clinical trials for high blood pressure. These effects were generally described as mild and temporary.


Q: Does Variace affect appetite or weight?

Changes in appetite and weight loss are noted in safety reports as uncommon adverse reactions. Changes in health status, such as appetite or weight changes, are typically discussed with a healthcare provider.


Q: What does official information say about using Variace with liver problems?

Official guidelines indicate that patients with existing hepatic impairment (liver problems) should use this medicine with caution and under close medical supervision. While rare, the potential for serious adverse reactions, such as acute hepatic failure (severe liver damage), is noted in regulatory safety information, and dose adjustments may be needed.


Q: Does Variace affect fertility or the ability to have children?

Official prescribing information does not list human fertility issues as a commonly reported adverse reaction. However, use is prohibited during the second and third trimesters of pregnancy due to risks to the fetus, and the medicine is not recommended for nursing mothers.


Q: Is it true that Variace can interact with grapefruit?

There is no explicit warning or statement in the official prescribing information for the active ingredient about a specific interaction with grapefruit or grapefruit juice. The official documents primarily focus on known drug-drug interactions related to other medications.


Q: Does Variace affect blood pressure?

Yes, Variace is primarily indicated for lowering and stabilizing high blood pressure (hypertension). However, official warnings also note that it may cause symptomatic low blood pressure (hypotension), particularly when treatment is initiated or after a dose change.


Q: Can Variace be taken along with vitamins or supplements?

The official label specifies a known interaction risk with certain supplements, particularly those that increase potassium levels, such as potassium supplements or salt substitutes containing potassium. The use of these substances together is generally determined by a healthcare provider.


Q: Is Variace a high-risk medication?

Variace is a prescription medication with officially documented safety constraints. Regulatory warnings highlight the potential for serious, yet rare, adverse reactions, including angioedema (severe swelling) and fetal toxicity if used during the later stages of pregnancy. These warnings define the critical safety boundaries for its appropriate use.


Q: How should I handle interactions listed for Variace?

The official label identifies certain drug combinations that are contraindicated, meaning they must not be used together. For other potentially interacting medicines, the label indicates that close medical monitoring or a dose adjustment may be necessary. Management of drug interactions is a clinical determination made by a healthcare provider.


Q: Does taking Variace affect my ability to drive or operate machinery?

Official documents advise that the ability to drive or operate complex machinery may be impaired by some common side effects, specifically dizziness and fatigue. The potential for these effects suggests that individuals should be aware of possible impairment, particularly when beginning treatment or after a dose change.


Q: What is the evidence supporting the use of Variace?

Evidence from controlled clinical trials supports the use of Variace for treating high blood pressure. It is also indicated for reducing the risk of major cardiovascular events, such as heart attack and stroke, in patients determined to be at high risk, and for treating heart failure after a heart attack.


Q: What makes Variace different from other drugs for the same condition?

Variace belongs to the ACE inhibitor class of drugs, which share a similar mechanism of action. However, the official prescribing information includes specific, proven indications, supported by major clinical studies, for reducing the risk of cardiovascular outcomes in high-risk patients. This specific indication may not be present on the labels of all other ACE inhibitors.


Q: How do I know if the Variace is working for me?

If used for high blood pressure, a patient may not feel any different because hypertension often lacks noticeable symptoms. Efficacy is determined by blood pressure measurements aligning with targets established by a healthcare provider. For other indications, effects may take several weeks or months to become apparent.


Q: Are there any skin-related side effects from taking Variace?

The most serious skin-related risk highlighted in regulatory documents is angioedema, which is rapid swelling of the face, lips, tongue, or throat and is potentially life-threatening. Other, less frequent skin-related adverse events have also been noted in safety reports.


Q: How is Variace usually packaged or supplied?

Variace is supplied for oral administration as hard gelatin capsules. Official prescribing information lists the specific packaging details, including the capsule color, identifying markings, and the range of strengths available.


Q: Is Variace used for other health issues besides the main one?

Yes. Beyond its primary use for high blood pressure, Variace is officially indicated for reducing the risk of stroke, heart attack, and cardiovascular death in certain high-risk individuals, and for the management of heart failure following a heart attack.


Q: Can teenagers or children be prescribed Variace?

Official regulatory documents state that the medicine is not recommended for use in children and adolescents. The safety and effectiveness of Variace in pediatric patients, defined as those under 18 years of age, have not been established in the official prescribing information.


Q: Is Variace a newly approved drug?

No. The active ingredient, ramipril, was first approved by the U.S. Food and Drug Administration (FDA) in the early 1990s for use in treating high blood pressure. Therefore, it has been in therapeutic use for several decades.


Q: What is the maximum duration Variace is typically studied for?

Clinical trials for the long-term use of Variace in high-risk cardiovascular patients included extended follow-up periods, with some major studies averaging over four years of treatment. Trials demonstrate that the drug maintains a sustained effect during long-term therapy.


Q: Are there different strengths or formulations of Variace?

Yes. The active ingredient is available in both tablets and hard capsules for oral use. The capsules are officially supplied in a range of strengths, typically including 1.25 mg, 2.5 mg, 5 mg, and 10 mg.


Q: Is there a generic version of Variace available?

Yes. The active ingredient, ramipril, is widely available as a generic medication, in addition to its branded formulations.


Q: Does the time of day I take Variace matter?

The medicine is generally prescribed to be taken once daily, though some specific regimens may call for a twice-daily dose. Official documents state it may be taken with or without food. While no specific time of day is mandated, consistency in the dosing schedule is an expected element of the treatment plan.


How should Variace be stored and disposed of?

Official Storage Conditions

Variace (ramipril) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and direct light. It is mandatory to keep Variace from freezing.

Required Storage Constraint Condition
Temperature Range 20 C to 25 C
Environmental Protection Protect from freezing, heat, and moisture
Container Rule Keep tightly closed with a safety closure

Handling and Disposal

For safety, the medication must be stored out of the sight and reach of children at all times. Disposal of unused or expired Variace must follow official regulatory guidance. Patients are instructed to consult a healthcare professional regarding proper disposal and must not flush the medicine down the toilet or pour it down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Variace found in:

A-Z Index: